CN108836974A - Hypoglycemic and liver-protecting combination based on multipath adjustment mechanism - Google Patents
Hypoglycemic and liver-protecting combination based on multipath adjustment mechanism Download PDFInfo
- Publication number
- CN108836974A CN108836974A CN201810499839.2A CN201810499839A CN108836974A CN 108836974 A CN108836974 A CN 108836974A CN 201810499839 A CN201810499839 A CN 201810499839A CN 108836974 A CN108836974 A CN 108836974A
- Authority
- CN
- China
- Prior art keywords
- liver
- group
- mannan
- oligosaccharides
- hypoglycemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 25
- 230000007246 mechanism Effects 0.000 title abstract description 6
- 241000405414 Rehmannia Species 0.000 claims abstract description 31
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims abstract description 29
- 210000004185 liver Anatomy 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 19
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 210000003484 anatomy Anatomy 0.000 abstract description 2
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 34
- 239000008103 glucose Substances 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 235000013305 food Nutrition 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 7
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000004258 portal system Anatomy 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- -1 White Chemical compound 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- XPYBSIWDXQFNMH-UYFOZJQFSA-N keto-D-fructose 1,6-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UYFOZJQFSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical group COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of hypoglycemic and liver-protecting combinations, in parts by weight, include at least rehmannia root oligose 20-80 parts by weight and mannan-oligosaccharides 20-80 parts by weight.The present invention uses rehmannia root oligose and mannan-oligosaccharides simultaneously, pass through the anatomical structure and function of enteron aisle and liver, and intestinal microecology balance, intestines-liver axis is set to interact under number of mechanisms, and form powerful balance, collaboration, synergistic effect, make its blood sugar decreasing effect and maintain normal glycemic levels and liver protection effect, is all significantly improved than rehmannia root oligose is used alone or mannan-oligosaccharides are used alone.
Description
Technical field
The invention belongs to medical treatment, health care and field of food, and in particular to a kind of based on the hypoglycemic of multipath adjustment mechanism
And liver-protecting combination.
Background technique
Safety and health are 21st century the focus of world attention problems.Diabetes are after tumour, cardiovascular and cerebrovascular disease
Third position is come, is one of the chronic disease for seriously endangering human health.Diabetes are a kind of because of body hypoinsulinism
Or a series of carbohydrates caused by insulin resistance etc., lipid, protein metabolism derangement syndrome.Fat metabolism is caused by diabetes
Disorder influences liver function, causes liver enlargement, and dysfunction of liver even results in cirrhosis.Both at home and abroad to the main of diabetes
Treatment method is manual injection's insulin or oral hypoglycemic drug, but these treatment methods are difficult to precisely adjust there are dosage,
The prediction of effect of drugs difficulty, to pain caused by patient, by force, easily there is the impaired phenomenon of liver kidney in big, toxic side effect.
Liver is the maincenter sexual organ of organism metabolism, in gluconeogenesis, Glycogen synthesis, storage, and as the glucose of the energy
Intake, utilization and release aspect play important adjustment effect.The glycometabolism of liver is not only that the physiological activity of itself provides
Energy, the also energy demand for other organs provide glucose.Liver is closely bound up with pathoglycemia, pertinent literature report, liver
Dirty insulin resistance will cause hyperglycemia disease；Patient with liver cirrhosis has abnormal carbohydrate metabolism phenomenon；Patients with Fatty Liver has obviously
Insulin resistance；Acute serious hepatitis patient Yi Yinqi liver source property hyperglycemia, with the recovery of liver function, blood glucose is also extensive
It is multiple normal, therefore illustrate that liver has critical role in glycometabolism, and closely related with diabetes.
Intestinal mucosa constitutes the first line of defence that human body is contacted with exogenous material, and the second that liver then constitutes human body is anti-
Line.Enteron aisle and liver originate from and anatomically in close relations related in embryo, and the embryo origin of two organs is identical, i.e. anterior intestine,
The precursor of gut-associated lymphoid cell originates from developmental liver.Two organs are mutual by portal vein anatomically
Connection, the blood of liver about 80% come from portal vein, and intestinal mucosa lymphocyte is migrated between two organs of liver and enteron aisle to anti-
Imperial pathogen passes through gut barrier and reaches liver, and the immune response of enteron aisle discharges a large amount of proinflammatory cytokine, can pass through
Portal vein enters liver；Liver itself has certain regulatory function to the lymphocyte in enteron aisle source simultaneously.Work as intestinal lymphoid
Cell function gets muddled, and can cause the generation of liver sausage lesion and its related complication, forms dissection and function is all relevant
Intestines-liver axis.
Under normal circumstances, intestine beneficial bacteria colony can secrete beneficial substance such as acetic acid, butyric acid, hormone etc., and endotoxin
Content be also considerably reduced, these benefit materials enter liver by portal system with the blood flow of enteron aisle, subsequently enter body and follow
Ring promotes the normal physiological of human body to be metabolized.When intestinal bacilli illness, intestinal permeability may make to increase, gut barrier function
It can reduce, harmful bacteria meeting mass propagation, cracking, and secrete a large amount of endotoxin, into portal system, liver be reached, into body
Circulation, finally induces a variety of diseases.
The above enteron aisle and liver are balanced by anatomical structure and function and intestinal microecology, make intestines-liver axis in a variety of machines
It interacts under system.
Konjaku glucomannan（KGM）It is that D-Glucose and D-MANNOSE are miscellaneous more in conjunction with being formed by β -1,4 glycosidic bond
Sugar, the glycan molecule degree of polymerization that is averaged is between 1000~10000.Since KGM is there are molecule aggregation degree is higher, viscosity compared with
Greatly, the defects of solubility is smaller, therefore the application of natural KGM is limited to a certain extent.Difference can be generated through degradation in KGM
The Glucomannan of the degree of polymerization, wherein mannan-oligosaccharides are the lower a kind of sugar of the degree of polymerization, and the degree of polymerization of glycan molecule is at 2-10
Sugar has been widely used in food, chemical industry and medicine and other fields.
Some effect experiments and clinical and experimental study in recent years show that the adjustable intestinal flora of mannan-oligosaccharides is disorderly
Disorderly, has effects that hypoglycemic.
In addition, a kind of be directed to diabetes special medicine food, liver function can be improved again while having reduces blood glucose,
Just seem especially urgent and important for the patient simultaneously with liver diseases and diabetes.
Summary of the invention
Technical problem to be solved by the invention is to provide a kind of hypoglycemic and liver-protecting combination, the hypoglycemic and protect liver groups
It closes object and includes at least rehmannia root oligose and mannan-oligosaccharides.Rehmannia root oligose and mannan-oligosaccharides are used simultaneously, pass through intestines liver mechanism shaft
And form powerful balance, collaboration, synergistic effect, make its blood sugar decreasing effect and liver protection effect than be used alone rehmannia root oligose or
Mannan-oligosaccharides are used alone all to significantly improve, composite formula of the invention is simple, efficient, practical.
The technical proposal adopted by the invention to solve the above technical problems is that：
A kind of hypoglycemic and liver-protecting combination includes at least rehmannia root oligose 20-80 parts by weight and sweet dew in parts by weight
Oligosaccharide 20-80 parts by weight.
In further technical solution, described hypoglycemic and liver-protecting combination, including 60 parts by weight of rehmannia root oligose and sweet
Reveal 40 parts by weight of oligosaccharide.
In technical solution of the present invention, rehmannia root oligose source：It buys from Shaanxi Pa Nier Biotechnology Co., Ltd
Pioneer, HPLC detection, content 80%.
In technical solution of the present invention, mannan-oligosaccharides source：Inventor is according to Chinese invention patent
The preparation of CN201110305324.2 the method, liquid chromatogram and Mass Spectrometer Method, total reducing sugar：≧99.5%；2 sugar of functional component sweet dew ~
10 sugar of sweet dew：≧98.0%；Wherein 4 sugar of sweet dew ~ sweet dew, 8 sugar accounts for 85% or more.
In one embodiment, the present composition is used for special medicine formula food.
According to《Special medicine purposes formula food general rule》Requirement, in conjunction with the constitutive character of diabetic, the present invention
A kind of hypoglycemic and protect liver non-whole nutritional formula food is also provided, including following component by weight：Rehmannia root oligose 42g is sweet
Reveal oligosaccharide 28g, collagen peptide 10g, a variety of amino acid 1 0g, multivitamin 6g, several mineral materials 4g.
Above-mentioned hypoglycemic and protect liver non-whole nutritional formula food preparation method is as follows：
(1) sterilization processing is carried out using ultraviolet irradiation to each component；
(2) component is crossed into 60 meshes, then by each component weight weighing in formula；
(3) load weighted component is placed in together in mixing machine and is uniformly mixed, cross 60 meshes；
(4) will products obtained therefrom specification as required after mixing, carry out quantitative separating.
All operations are required to《Special medicine purposes formula food Good Manufacture Practice》It is required that clean environment in into
Row.
Products of the present invention has the following advantages that：
（1）The present composition includes 60 parts by weight of rehmannia root oligose, 40 parts by weight of mannan-oligosaccharides, and composition of the invention is suitable
For food, drug or field of health care products, to reduce the blood sugar concentration of diabetic.
（2）The present composition uses rehmannia root oligose and mannan-oligosaccharides simultaneously.
Rehmannia root oligose can improve impaired pancreatic tissue, adjust insulin and its demodulate hormone secretion, generate hepatic glycogen
Increase, reduces gluconeogenesis by reducing glucose phosphate enzymatic activity, to further blood glucose be made to decline.
Mannan-oligosaccharides have effects that be proliferated beneficial bacterium, inhibit harmful bacteria, when Bifidobacterium, bacteroid, cream in enteron aisle
When the profitable strains quantity such as bacillus obviously increases, enteric microorganism can secrete a large amount of beneficial substance such as acetic acid, butyric acid, eggs
White, hormone etc., and endotoxic content is also considerably reduced, these substances enter liver by portal system with the blood flow of enteron aisle
Enter body circulation, acetic acid and butyric acid afterwards by induction glucagon-like-peptide-1 (GLP-1) and polypeptide YY (PYY), improves internal
Glucose balance, so that the blood sugar concentration of type 2 diabetes patient be effectively reduced.
Rehmannia root oligose and mannan-oligosaccharides achieve the purpose that reduce blood glucose jointly by different action pathway, when their groups
It is combined, there is powerful balance, collaboration, synergistic effect, to improve and stabilize blood sugar decreasing effect.
（3）The rehmannia root oligose itself that the present composition is selected has protect liver effect, and mannan-oligosaccharides are then by adjusting intestines
Road colony balance and influence liver metabolism, form relevant to intestinal microecology balance intestines-liver mechanism shaft.Therefore present invention combination
Object not only has significant blood sugar decreasing effect, but also has good liver-protecting function, this dual synergistic function, to simultaneously
Patient with liver diseases and diabetes has special health care and clinical meaning.This is because improving liver function and drop at present
Low levels require prolonged administration of drugs, and the medication of two kinds of diseases conflicts with each other, and diabetes merge lesions of liver and kidney and suffer from
When person's medication, the situations such as the adjustment of dosage difficulty, the survey of effect difficulty can be faced, and liver kidney once occur and be damaged, many oral hypoglycemic agents
It cannot use, this just often results in attending to one thing and lose sight of another in treatment method, and merges liver function problem in China diabetic
It is more serious than other countries.
（4）Composition of the invention is suitable for food, drug or field of health care products, to reduce type 2 diabetes patient
Blood sugar concentration, and improve the liver function of patient simultaneously.
（5）Provided by the invention hypoglycemic and protect liver non-whole nutritional formula food can improve again while reducing blood glucose
Liver function.The food can be taken for a long time, will not generate side effect to human body, this is to simultaneously with liver diseases and diabetes
Just seem especially urgent and important for patient.
Specific embodiment
Embodiment 1
A kind of hypoglycemic and liver-protecting combination, is made of, composition and ratio can be following rehmannia root oligose and mannan-oligosaccharides
Combination, is shown in Table 1：
Table 1
The rehmannia root oligose source：Purchase is detected from Shaanxi Pa Nier Biotechnology Co., Ltd pioneer, HPLC, content
80%。
The mannan-oligosaccharides source：Inventor is according to Chinese invention patent CN201110305324.2 the method system
It is standby, liquid chromatogram and Mass Spectrometer Method, total reducing sugar：≧99.5%；2 sugar of functional component sweet dew ~ sweet dew, 10 sugar：≧98.0%；Wherein sweet dew 4
8 sugar of sugar ~ sweet dew accounts for 85% or more.
It is as follows to have hypoglycemic and liver-protecting function preparation method of composition containing said components：
(1) sterilization processing is carried out using ultraviolet irradiation to rehmannia root oligose and mannan-oligosaccharides first,
(2) raw material is crossed into 60 meshes, it is spare then by each component weight weighing in formula；
(3) load weighted raw material is placed in together in mixing machine and is uniformly mixed, cross 60 meshes；
(4) by products obtained therefrom, specification carries out quantitative separating as required.
Embodiment 2
Hypoglycemic and liver-protecting combination prepared by above-described embodiment 1 used below investigates it to the hypoglycemic of mouse by experiment
With protect liver effect.
The experiment of one effect of lowering blood sugar of Efficacy experiments
Choose the similar healthy rat of size and form, adaptable fed fasting 12h after a week is primary according to the concentration of 120mg/kg
Property intraperitoneal injection STZ（Be dissolved in the citric acid-sodium citrate buffer solution of 0 .1mol/L of pH4 .5, in be protected from light, ice bath save item
Matching while using under part）, docking takes blood to survey blood glucose after 3 days, and blood glucose value >=14.2mmol/L thinks Glycemia Decline success.It will
The successful rat of modeling is randomly divided into 5 groups, and every group 10, respectively model group, melbine group, rehmannia root oligose group, sweet dew is low
Glycan group, composition A group, composition B group, composition C group, composition D group.Separately take 10 same batch of healthy rats as normal right
According to group, grouping same day gastric infusion, normal group and model group are：Pure water, remaining each group are 200mg/kg.d,
Successive administration 30 days, 10 days after modeling, Rat Fast 12h is given within 20 days, surveys fasting blood-glucose；Respectively in successive administration 60
It, after 90 days, takes blood through femoral artery, extracts upper serum, measure glycosylated hemoglobin value.Glycosylated hemoglobin is hemoglobin
（Hb）With carbohydrate（Such as glucose, glucose 6-phosphate or 1,6- diphosphofructose）It is combined into, synthesized through non-enzymatic
Journey is slow and irreversible, concentration and red blood cell life span（It is 120 days average）It is related with the mean concentration of blood glucose in the period,
Do not changed by the big minor swing of daily plasma glucose concentration, also not by moving or food is influenced, therefore glycosylated hemoglobin
It is the mean blood glucose concentrations in past 6 ~ 10 weeks of reflection, this can provide reliable index to assess the control situation of blood glucose（Normal glucose
Change the 4-6% that content of hemoglobin is hemoglobin total amount）.Test result see the table below 2：
Table 2
Note：Each administration group is compared with model group, * P < 0.05, * * P < 0.01
The blood glucose and glycosylated hemoglobin value of normal rats are without significant change.
After diabetes rat treatment, the fasting blood sugar and glycosylated hemoglobin value of each administration group rat are compared with hyperglycemia model
Group, which has, significantly arrives extremely significant decline.
There is the composition group combined by rehmannia root oligose and mannan-oligosaccharides powerful balance, collaboration, synergy to make
With effect of the hypoglycemic effect of composition group than independent rehmannia root oligose and mannan-oligosaccharides is obvious, wherein composition D group
Effect is extremely significant.
Composition A group, composition B group, the composition C group combined by rehmannia root oligose and mannan-oligosaccharides, have
With hypoglycemic effect similar in drug control group melbine.The fasting blood sugar of composition D group rat last time measurement and
Glycosylated hemoglobin value is also lower than melbine drug control group, shows that composition D group tool is significantly reduced blood glucose function
Effect.After rat takes composition 90 days, the glycosylated hemoglobin value of composition D group is close to normal value.Illustrate composition D group
Fasting blood-glucose can be not only reduced, blood glucose can also be effectively controlled, so that blood glucose is chronically at a stabilization normal horizontal.
Two protect liver Efficacy experiments of Efficacy experiments
Selecting 60 ICR small white mouses is experimental animal, carries out the experiment of liver damage animal model, is randomly divided into 6 groups, respectively empty
White control group, model group, bifendate group, rehmannia root oligose group, mannan-oligosaccharides group, composition A group, composition B group, composition
C group, composition D group, each test group is primary by the daily stomach-filling of dosage shown in table 3, and continuous 6 days, blank control group and model group were given
Same amount pure water is given, after administration in the 6th day, in addition to same amount physiological saline is subcutaneously injected in blank control group, other each groups are injected respectively
0.5% carbon tetrachloride 10ml/kg weight, after 4h, each test group is administered once again, puts to death animal after the 7th day last dose 1h, takes
Hematometry serum hemolysis cellulose content separately takes thymus gland, spleen to weigh respectively and calculates liver index, the results are shown in Table 3：
Table 3
Note：Each group is compared with model group, * P < 0.05, * * P < 0.01
Test result shows that blank control group mouse serum hemolysis cellulose content, thymus gland, index and spleen index have pole compared with model group
Significantly increase, shows modeling success；Compared with model group, mice serum haemolysis cellulose content, index and spleen index have aobvious each administration group
It writes and increases, other than rehmannia root oligose group and mannan-oligosaccharides group, other each administration groups dramatically increase thymus index；Combination
Object A group, composition B group, composition C group, composition D group liver protection effect than individual rehmannia root oligose and mannan-oligosaccharides effect
Fruit is more significant, shows that rehmannia root oligose and mannan-oligosaccharides are combined, and has powerful balance, collaboration, synergistic effect；It is all
Composition A group, composition B group, composition C group, composition D group compared with positive control-bifendate group, enhancing liver damage
Also there is same or close effect in terms of hurting immune function of mice.
Embodiment 3
According to《Special medicine purposes formula food general rule》Requirement, it is a kind of hypoglycemic in conjunction with the constitutive character of diabetic
And protect liver non-whole nutritional formula food, including following component by weight：Rehmannia root oligose 42g, mannan-oligosaccharides 28g, collagen
Protein peptides 10g, a variety of amino acid 1 0g, multivitamin 6g, several mineral materials 4g.
Above-mentioned hypoglycemic and protect liver non-whole nutritional formula food preparation method is as follows：
(1) sterilization processing is carried out using ultraviolet irradiation to each component；
(2) component is crossed into 60 meshes, then by each component weight weighing in formula；
(3) load weighted component is placed in together in mixing machine and is uniformly mixed, cross 60 meshes；
(4) will products obtained therefrom specification as required after mixing, carry out quantitative separating.
All operations are required to《Special medicine purposes formula food Good Manufacture Practice》It is required that clean environment in into
Row.
Instructions of taking：The hypoglycemic and appropriate warm water of protect liver non-whole nutritional formula food is dissolved, i.e., it is drinkable.
Above description is not limitation of the present invention, and the present invention is also not limited to the example above.The art it is common
Within the essential scope of the present invention, the variations, modifications, additions or substitutions made also should belong to protection of the invention to technical staff
Range.
Claims (4)
1. a kind of hypoglycemic and liver-protecting combination, which is characterized in that in parts by weight, include at least rehmannia root oligose 20-80
Parts by weight and mannan-oligosaccharides 20-80 parts by weight.
2. the hypoglycemic and liver-protecting combination of one kind as described in claim 1, which is characterized in that in parts by weight, including
40 parts by weight of 60 parts by weight of rehmannia root oligose and mannan-oligosaccharides.
3. the hypoglycemic and liver-protecting combination of one kind as described in claim 1, which is characterized in that in parts by weight, including
20 parts by weight of 80 parts by weight of rehmannia root oligose and mannan-oligosaccharides.
4. the hypoglycemic and liver-protecting combination of one kind as described in claim 1, which is characterized in that in parts by weight, including
50 parts by weight of 50 parts by weight of rehmannia root oligose and mannan-oligosaccharides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499839.2A CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499839.2A CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108836974A true CN108836974A (en) | 2018-11-20 |
| CN108836974B CN108836974B (en) | 2020-09-29 |
Family
ID=64213282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810499839.2A Active CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108836974B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649335A (en) * | 2009-06-25 | 2010-02-17 | 中国食品发酵工业研究院 | Preparation method of high-purity alpha-1,6 trisaccharide |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
-
2018
- 2018-05-23 CN CN201810499839.2A patent/CN108836974B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649335A (en) * | 2009-06-25 | 2010-02-17 | 中国食品发酵工业研究院 | Preparation method of high-purity alpha-1,6 trisaccharide |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
Non-Patent Citations (2)
| Title |
|---|
| 康立新 等: "酶法制备甘露低聚糖", 《食品科技》 * |
| 王君明 等: "地黄多糖和寡糖的药理作用研究进展", 《中国老年学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108836974B (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lo et al. | The anti-hyperglycemic activity of the fruiting body of Cordyceps in diabetic rats induced by nicotinamide and streptozotocin | |
| Lo et al. | Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.: Fr. on glycemic responses in normal and diabetic rats | |
| Johnston et al. | Examination of the antiglycemic properties of vinegar in healthy adults | |
| US11771735B2 (en) | Composition for improving or preventing nonalcoholic fatty liver | |
| CN109221898A (en) | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide | |
| CN104971343A (en) | Application of defensins to aspect of preparation of medicine for treating metabolic syndrome | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN105661547A (en) | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement | |
| CA3022247C (en) | Composition for treating diabetic disease | |
| CN107206053A (en) | For treat cytopenia or reduce cytopenia duration phorbol ester composition and method | |
| CN103446166B (en) | Hepatic function remedial agent | |
| CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
| CN106573034B (en) | Marine peptides and fish nucleotides, compositions and uses thereof for lowering blood glucose | |
| GROZAVESCU et al. | Biochemical aspects of diabetes mellitus | |
| CN108836974A (en) | Hypoglycemic and liver-protecting combination based on multipath adjustment mechanism | |
| US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
| CN104784192B (en) | The application of freshwater mussel meat oligosaccharides in hypoglycemic drug is prepared and preparation method thereof | |
| KR100732614B1 (en) | A pharmaceutical composition for the prevention and treatment of obesity or diabetes mellitus comprising an extract of a puffer | |
| CN104524568B (en) | A kind of pharmaceutical composition for treating obesity and its application | |
| CN108294232A (en) | Nutritional staple food with function of blood sugar reduction | |
| CN107136499A (en) | Compound preparation for enhancing immunity of tumor patients after operation | |
| CN108578681A (en) | Exenatide is preparing the application in treating hepatic fibrosis medicines | |
| CN103705696A (en) | Method for preparing powder injection for treating diabetes by using aloes and Chinese yam | |
| CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |